share_log

Earnings Call Summary | Jaguar Health(JAGX.US) Q1 2024 Earnings Conference

Futu News ·  May 15 01:41  · Conference Call

The following is a summary of the Jaguar Health, Inc. (JAGX) Q1 2024 Earnings Call Transcript:

Financial Performance:

  • Jaguar Health reported a Q1 2024 net revenue of approximately $2.4 million, signaling a 20% increase year over year and a 4% increase quarter over quarter.

  • The company managed to reduce its operational loss to $8.2 million in Q1 2024 from $9.9 million in Q1 2023.

  • The net loss attributable to common shareholders also decreased to $9.2 million in Q1 2024, down from the $12.2 million reported in Q1 2023.

Business Progress:

  • Jaguar Health is expectantly waiting for the results from the OnTarget trial involving the drug Crofelemer for cancer therapy-related diarrhea.

  • The company is broadening its commercial footprint beyond HIV supportive care into cancer-related supportive care and will introduce the FDA-approved oral mucositis prescription Gelclair for the United States market.

  • They are also planning for early patient access for Crofelemer for intestinal failure in Europe by 2025.

  • The company is actively engaging with the oncology community through congresses and meetings, showcasing their commitment towards supporting cancer care.

More details: Jaguar Health IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment